Effect of Alpha Tocopherol and Psyllium on Lipid Levels in Dyslipidaemia Patients
NCT07610304
Dyslipidaemia, Dyslipidemias
Lahore, Pakistan
View Trial DetailsNCT Number: NCT01055977
Statins are the first choice treatment of dyslipidemia, a major contributor to cardiovascular diseases. Statins also have enough evidence to demonstrate decrease of morbidity and mortality from cardiovascular diseases. Even though statin therapy is effective treatment of dyslipidaemia not all patients reach the goal levels.
The aim of the study is to estimate proportion of patients who achieved the therapeutic goal (LDL-C. total cholesterol, HDL-C and triglycerides levels) after at least one year of a statin therapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Research Site, Benešov, Czechia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Time frame: one year
Time frame: one year
Time frame: one year
Time frame: one year
AstraZeneca
Industry
Acronym: STEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07610304
Dyslipidaemia, Dyslipidemias
Lahore, Pakistan
View Trial DetailsNCT07497776
Dyslipidaemia, Dyslipidemias
Dhaka, Dhaka Division, Bangladesh
View Trial DetailsNCT07492264
Dyslipidaemia, Dyslipidemias
Siena, Italy
View Trial DetailsNCT05979428
Dyslipidaemia, Dyslipidemias
Cypress, California, United States
View Trial Details